Onconetix Inc

Finanzas de Onconetix Inc (ONCO)

$0.598

+0.155 (+25.98%)Al cierre

Rentabilidad y márgenes de ONCO

Evaluating the bottom line, Onconetix Inc maintains a gross margin of 25.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13112.09%, while the net margin is -16748.27%. These profitability ratios, combined with a Return on Equity (ROE) of -105.23%, provide a clear picture of how effectively ONCO converts its operational activities into shareholder value.

Comparativa sectorial de ONCO

In the context of the broader market, ONCO competes directly with industry leaders such as PRFX and HELP. With a market capitalization of $3.13M, it holds a significant position in the sector. When comparing efficiency, ONCO's gross margin of 25.13% stands against PRFX's -3557.14% and HELP's N/A. Such benchmarking helps identify whether Onconetix Inc is trading at a premium or discount relative to its financial performance.

Desempeño financiero de Onconetix Inc

Onconetix has shown a concerning trend in financial performance, with a net income of -$2,867,303 in Q2 2026 and a gross margin that has decreased to 25.13%. This indicates potential operational challenges and a lack of profitability.

Financials

FY2026Q2
YoY:
-83.92%
17.12K
Total Revenue
FY2026Q2
YoY:
+67.34%
-2.25M
Operating Profit
FY2026Q2
YoY:
+20.86%
-2.87M
Net Income after Tax
FY2026Q2
YoY:
-99.46%
-1.28
EPS - Diluted
FY2026Q2
YoY:
+36.00%
-1.92M
Free Cash Flow
FY2026Q2
YoY:
-62.04%
25.13
Gross Profit Margin - %
FY2024Q4
YoY:
-98.76%
-416.95
FCF Margin - %
FY2026Q2
YoY:
+651.80%
-16.75K
Net Margin - %

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar